Conventional DMARDs

What this option is

RA can damage joints over time because of ongoing inflammation. Some medicines try to change that course, rather than only easing pain for a while.

DMARD stands for disease-modifying antirheumatic drug. These medicines are used to control the inflammation driving RA and help protect joints from ongoing damage. Methotrexate is usually the main conventional DMARD used first.

Other conventional DMARDs include leflunomide, sulfasalazine, and hydroxychloroquine. Depending on the situation, they may be used instead of methotrexate or combined with it.

Why methotrexate is usually first

Major treatment guidelines generally recommend methotrexate as the first disease-modifying medicine for many adults with active RA. The evidence supporting that starting position is well established, and methotrexate can remain part of the plan if another medicine needs to be added.

Starting with methotrexate doesn't mean staying on methotrexate alone indefinitely. If RA remains active, another conventional DMARD may be added, or the plan may move beyond conventional DMARDs.

Treat-to-target is a simple idea

Treat-to-target means treatment has a goal, and if you're not reaching it, the plan shouldn't just continue unchanged.

Your rheumatology team regularly checks how active your RA is. The goal is usually remission or low disease activity. If the disease remains too active after enough time to judge the treatment, the next step may be adjusting or changing therapy.

Evidence comparing this kind of targeted follow-up with more routine care supports better disease-activity and remission outcomes on average. It isn't a guarantee that every person will reach remission.

Safety blood tests and disease-activity checks answer different questions. Blood tests can help show whether a medicine is safe for you to continue. They don't necessarily show whether your RA is controlled well enough.

What taking part usually involves

• Taking methotrexate on a weekly schedule, or another conventional DMARD according to its schedule. Methotrexate is often taken by mouth. Some people take it by injection instead.
• Having regular blood tests to watch for side effects, and visits to check whether the RA itself is improving.
• Allowing enough time to judge the response. These medicines don't work immediately.
• Sometimes using a steroid for short-term symptom control while disease-modifying treatment takes effect.
• Knowing when the plan will be reassessed, and what happens if the disease is still too active.

When the first plan isn't enough

If RA is still too active after enough time to judge the first treatment, monitoring alone isn't the answer. The treatment plan may need to change.

That can mean adjusting conventional DMARDs or moving to advanced treatments such as biologics or JAK inhibitors.

What might change the first choice?

Methotrexate is the usual first step for many adults, but it isn't right for everyone. Other health conditions, pregnancy or fertility plans, previous treatment, and whether methotrexate is suitable for you can affect the choice.

Those details belong in a clinical visit. The overall strategy is still the same: choose a disease-modifying plan, check whether it's controlling the RA well enough, and change course when it isn't.